Kornimate/medical-research-clean huggingface dataset:
neurodynamic mobilization and foam rolling

Conditions: Exercise-induced Muscle Damage; Movement Disorders; Nerve Pain

Summary: the purpose of this study was to assess the acute effects of a single nm treatment session on doms and to compare them with those of one foam roller (fr) session. following the damaging plyometric exercise bout, the participants were randomly assigned in a counter-balanced fashion to either a fr or nm treatment group; treatments were administered 48-h post-exercise. the dependent variables were recorded before the exercise, 48-h post-exercise before treatment, and immediately post-treatment.

currently, the foam-rolling massage is often used by athletes from many sports. however, there are a few studies on the effects of foam-rolling massage and they have conflicting results regarding the improvements in rom and muscular performance. in contrast, neurodynamic mobilization (nm) is a manual therapy method used to assess and treat neuromuscular disorders. it includes gliding techniques and tensile techniques. gliding techniques or "sliders" are intended to produce a sliding movement between neural structures and adjacent nonneural tissues. nm has been shown to reduce pain and soreness and improve rom. however, no studies have investigated its effects after exercise-induced muscle soreness or doms.

Eligibility criteria:
inclusion criteria: * all subjects were moderately active (category 2) as assessed by the international physical activity questionnaire (ipaq) questionnaire (craig et al., 2003). * none of the subjects had a recent history of intensive training, heavy eccentric resistance, or plyometric exercise, and all subjects were free from musculoskeletal disorders in the last year. * all subjects were asked to refrain from unaccustomed exercise during the experimental period, and the subjects abstained from all medications and dietary supplements during the experimental period and between testing sessions. exclusion criteria: * sedentary * patients with pain

Keywords: pain
evaluation of cardiac ct appropriateness at second-generation 320-row ct

Conditions: Coronary Artery Disease; Cardiac CT

Summary: the influence of the second-generation 320-row area-detector ct (adct) on the clinical indications and appropriateness of cardiac ct has not been adequately investigated. the purpose of the survey is to assess the distribution of appropriateness ratings and test outcomes of cardiac ct with second-generation adct.


Eligibility criteria:
inclusion criteria: * indicated for coronary ct assessment exclusion criteria: * aortic disease * pulmonary embolism * severe arrhythmia * severe heart failure * allergy for iodinated contrast agent

Keywords: coronary artery disease cardiac ct appropriate use criteria (auc)
a study of pemetrexed plus cisplatin in patients with refractory soft tissue sarcoma

Conditions: Sarcoma

Summary: the yearly incidence of soft-tissue sarcomas(sts) in the usa is roughly 11,280 cases, and metastatic sts have a median overall survival of about 12 months. after the standard 1st line chemotherapy with doxorubicin, the only a few treatment option is available. recently, pemetrexed, a novel multitargeted antifolate, has shown modest activity as a single agent lung cancer and mesothelioma. in patients with refractory sts, pemetrexed is well tolerated and moderately effective. based on the background, investigators planned to conduct the phase ii trial of pemetrexed in combination with cisplatin for metastatic/recurred soft-tissue sarcomas.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed advanced bone and soft tissue sarcoma with prior chemotherapy including anthracycline or ifosfamide 2. measurable or evaluable disease (recist 1.1.) 3. age ≥19 years 4. ecog performance status of 0-2 5. adequate laboratory findings * absolute neutrophil count (anc) ≥ 1500 /µl * platelet count ≥ 75,000/ µl * serum creatinine \< 1.5 x upper limit of normal (uln) * ast (sgot) and alt (sgpt) \< 3 x upper limit of normal (uln) * total bilirubin \<1.5 x upper limit of normal (uln) 6. more than 3 months of expected survival 7. provision of written informed consent prior to any study procedure exclusion criteria: 1. patient who has had chemotherapy, radiotherapy, or biological therapy within 2 weeks prior to entering the study' 2. patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study. 3. resectable lung metastases 4. uncontrolled or active cns metastasis and/or carcinomatous meningitis 5. other co-existing malignancies or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma, thyroid cancer or cervical cancer in situ. 6. uncontrolled medical conditions
comparison between low level laser therapy and active oxygen releasing gel on wound healing cleft lip patients

Conditions: Cleft Lip

Summary: the study was performed on secondary cleft lip scars

the study aimed at comparing and evaluation the effect of low-level diode laser and the effect of active oxygen releasing gel o3 (blue-m gel) topical application on healing outcome in secondary cleft lip correction.

Eligibility criteria:
inclusion criteria: 1. age: can be done in any time after six months from the previous surgery if it severely disfiguring or in the preschool stage for children the time of surgery should be based on the severity of deformities 2. primary cleft lip repair was done 3. secondary lip repair with or without nose correction is indicated 4. the patient didn't undergo any surgeries procedures in the last 6 months exclusion criteria: 1. previously subjected to secondary lip repair surgery. 2. syndromic cleft lip patient. 3. patient reporting abnormal reaction or scar healing in the previous surgery 4. smoking patients

Keywords: low level laser cleft lip scars active oxygen releasing
aerosol cyclosporine for prevention of lung rejection

Conditions: Lung Diseases

Summary: to evaluate the efficacy of aerosolized cyclosporine given in addition to the standard oral immunosuppressive drug regimen, in preventing acute rejection immediately after lung transplantation

background: success with lung transplantation has largely been due to the introduction of cyclosporine which has proved effective in controlling lung allograft rejection. nevertheless, acute and chronic rejection are prevalent in spite of immunosuppressive drug regimens based on oral cyclosporine. in fact, rejection is more common in recipients of lung allografts than those who receive other solid organs. acute rejection is treated with pulsed methylprednisolone and anti-lymphocyte globulin and consequently recipients are subject to increased risk of infection and drug toxicity. the hypothesis tested in the study was that delivery of cyclosporine to the transplanted lung by aerosol inhalation would achieve higher concentrations of cyclosporine in the graft than when it was delivered via the bloodstream and that higher concentrations in the graft would prevent rejection more effectively than systemic immune suppression with the same or reduced toxicity. cellular rejection occured in over 90% of the patients within the first year and often progressed to obliterative bronchiolitis (ob) which was the most common cause of death one year after transplant. in 1988, the lung transplant group at the university of pittsburgh decided to pursue cyclosporine aerosol for the treatment for acute rejection. after animal testing, initial human experiments were performed, which suggested that cyclosporine aerosol decreased the prevalence of acute rejection and the development of obliterative bronchiolitis. design narrative: this prospective double blind randomized trial was designed to evaluate the efficacy of cyclosporine aerosol versus placebo aerosol as an adjuvant to oral immunosuppression with tacrolimus, prednisone, and azathioprine. the hypotheses tested included: 1) acute rejection would be lower in the patients receiving cyclosporine aerosol, 2) maintenance cyclosporine aerosol would result in reduced incidence of ob, 3) cytokines and chemokine release would be suppressed, 4) patients receiving cyclosporine aerosol would require less systemic immunosuppression and 5) there would be a lower incidence of opportunistic and bacterial infections as a consequence of more effective immunosuppressive therapy. another specific aim of the study was to determine the optimal dose of cyclosporine aerosol that reduced rejection and/or ob and to correlate radioisotopically labeled inhalation studies with more easily measurable indices that affected the deposition of aerosolized medications. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record

Eligibility criteria:
no eligibility criteria
tdcs in mcs: repeated stimulations

Conditions: Patients in Minimally Conscious State After a Severe Brain Injury (e.g., Anoxia, Traumatic Brain Injury, Stroke)

Summary: in this study researchers will apply transcranial direct current stimulation (tdcs) for 5 consecutive days in chronic patients in minimally conscious state (mcs). 2 sessions of 5 days of stimulation will be realized, one anodal and one sham. after each stimulation, behavioral improvement will be assessed with the coma recovery scale revised (crs-r). a final assessment will be done one week after the end of the sessions to assess the long term effect of the tdcs.

positive effects of tdcs in patients in mcs was showed in a recent study published in neurology. but the effects went down after 1 or 2 hours. to increase the lasting of the effects, a new study will evaluate the effects of tdcs on the left prefrontal dorsolateral cortex for 5 consecutive days in chronic patients in mcs. 2 sessions of 5 days of stimulation will be realized, one session will be real (anodal stimulation) and one placebo (sham stimulation). after each stimulation, behavioral improvement will be assessed with the coma recovery scale revised (crs-r). a final assessment will be done one week after the end of the sessions to assess the long term effect of the tdcs. researchers expected to see an improvement of the crs-r total score at the end of the anodal session and that this improvement persists for a week.

Eligibility criteria:
inclusion criteria: * post comatose patients * patients in minimally conscious state * patients with stable condition * patients free of sedative drugs and na+ or ca++ blockers (e.g., carbamazepine) or nmda receptor antagonist (e.g., dextromethorphan) exclusion criteria: * premorbid neurology antecedent * patients in coma or vegetative state * patients \< 3 months after the acute brain injury * patients with a metallic cerebral implant or a pacemaker (in line with the safety criteria for tdcs in humans)

Keywords: disorders of consciousness minimally conscious state traumatic brain injury stroke transcranial direct current stimulation
new proteins in body fluids as potential biomarker for alzheimer's disease: a pilot study

Conditions: Alzheimer Disease, Late Onset

Summary: alzheimer's disease (ad) is the most common neurodegenerative disorder afflicting the elderly. currently, some biochemical tests performed on cerebrospinal fluid (csf) samples have demonstrated to discriminate to some extend between ad and non-ad individuals based on the levels of tau, phospho-tau or aβ42. we aim to investigate newly identified proteins whose levels increase during the braak stages of ad that are accessible in other body fluids such as blood, urine or saliva. the detection of these proteins would allow performing simple tests in case its levels were confirmed to be associated with the ad pathology.

we do not desire to provide a more extensive description

Eligibility criteria:
inclusion criteria: - mild to moderate ad exclusion criteria: -
single injection of regn475/sar164877 in treatment of vertebral fracture pain

Conditions: Back Pain

Summary: primary objective was to demonstrate the activity of regn475/sar164877 in reducing the pain associated with vertebral fracture. secondary objectives were: * to assess the safety and tolerability of regn475/sar164877 in patients with vertebral fracture pain; * to characterize the pharmacokinetic and immunogenicity profiles of regn475/sar164877 in this population.

the duration of the study period for each participant was up to 13 weeks, including a screening period up to 5 days, and 12-week follow-up after the injection.

Eligibility criteria:
inclusion criteria: - moderate to severe pain due to non-traumatic vertebral fracture associated with osteoporosis. exclusion criteria: * mild pain score on the pain intensity-numeric rating scale \[pi-nrs\] at screening and randomization visits; * narcotic addiction; * post-fracture vertebral instability; * unwillingness to use study-defined rescue analgesia exclusively. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
cognitive behavioral therapy (cbt) for late life anxiety

Conditions: Generalized Anxiety Disorder

Summary: the purpose of this research study is to assess the acceptability and feasibility of the implementation strategy and fidelity of cognitive-behavioral therapy (cbt) for older adults with generalized anxiety disorder.

all participants will receive cbt. each subject will be given a workbook and each chapter in the workbook provides information about a different coping strategy for managing worry and anxiety. there will be a daily assignment in the workbook to complete before a call with the personal study coach. for 10 weeks, participants will have a 45-50 minute session (telephone or video) each week with their study coach. these calls will be confidential. the participant and the personal study coach will review the assigned chapter and completed homework during the weekly telephone sessions. participants will also fill out questionnaires before starting sessions, when completing all 10 sessions, and 6 months after completing sessions.

Eligibility criteria:
inclusion criteria: * participants who have had an outpatient visit to an atrium provider * at least one of the following: any diagnosis of an anxiety or depressive disorder; anxiety, depression, or sleep disturbance as a symptom in the problem list or in the note; and use of anxiolytic, anti-depressant, and sleep aide medications. exclusion criteria: * diagnosis of dementia or cognitive impairment in the problem list

Keywords: late-life anxiety aging cognitive-behavioral therapy
pet/ct in evaluating response to chemotherapy in patients with breast cancer

Conditions: HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

Summary: this phase i trial studies the side effects of positron emission tomography (pet)/computed tomography (ct) in evaluating response to chemotherapy in patients with breast cancer. comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

primary objectives: i. study fludeoxyglucose \[18f\] 2'-fluoro-5-methyl-1-beta-d-arabinofuranosyluracil-clevudine (fmau) (fluorine f 18-clevudine ) in 10 patients with known breast cancer to obtain data on safety, circulating metabolite, tumor imaging feasibility, and radiation dosimetry. ii. assess the potential utility of fmau-pet in the imaging evaluation of chemotherapeutic response in 15 patients with breast cancer. outline: patients receive fluorine f18-clevudine intravenously (iv) over 1 minute and then undergo pet/ct scan at baseline. patients with human epidermal growth factor receptor 2 positive (her2+) breast cancer also undergo fluorine f 18-clevudine pet/ct scan 2-3 weeks after the first course of treatment and after completion of treatment. after completion of study treatment, patients are followed up at 24 hours.

Eligibility criteria:
inclusion criteria: * inclusion criteria for aim 1: * scheduled to receive therapy with trastuzumab plus chemotherapy as part of standard care * have one or more breast tumors visualized by conventional pet/ct, ct or magnetic resonance imaging (mri) prior to the pet fmau study; pet/ct should be within a week prior to 18-f fmau inclusion criteria for aim 2: * have been diagnosed with a her2+ invasive cancer of the breast * scheduled to receive pre-operative therapy with trastuzumab plus chemotherapy as part of standard care * have one or more breast tumors visualized by conventional pet/ct, ct or mri prior to the pet fmau study; pet/ct should be within a week prior to 18-f fmau exclusion criteria: * have undergone chemotherapy or radiation therapy within the previous one month * women of childbearing potential, unless they have had a negative urine human chorionic gonadotropin (hcg) within the previous 24 hours of the procedure * patients who have had surgery at the site of the suspected lesion within 1 month
exercise intervention to rescue the adverse effect of preterm birth on cardiovascular and pulmonary health.

Conditions: Prematurity; Extreme

Summary: in spite of advances in neonatal intensive care allowing the first generation survivors of extreme prematurity to now reach young adulthood, these individuals present with reduced exercise capacity; a strong predictor of later chronic disease and mortality. the reason why individuals born preterm have exercise limitation remains unclear and may be a consequence of impact of preterm birth and associated neonatal difficulties on the development of organs important for exercise, namely the lungs, the heart, the vessels (which bring blood and oxygen to the muscles) and the muscles. it is well known that exercise benefits overall health in at-risk as well diseased populations. however, whether exercise training can improve fitness in young adults born preterm was not demonstrated and whether the cardiovascular, pulmonary and muscle impairments associated with preterm birth are reversible through exercise intervention in young adulthood is unknown.

the investigators postulate that a 14-week exercise intervention will improve exercise capacity in preterm adults, as seen in other at-risk populations, in correlation with measures of vascular health, heart and muscle perfusion and oxygenation, and pulmonary function detected by cutting edge and highly sensitive imaging and circulating biomarkers. these markers are more sensitive to pre-disease changes than traditional health measures, and are largely unexplored in preterm populations. the investigators will: 1. determine whether a 14-week supervised exercise training improves exercise capacity in young adults (18-29 years old) born very preterm at \<29 weeks gestational age. 2. examine whether improvement in exercise capacity is associated with changes in (a) markers of vascular health including circulating endothelial progenitor cells and microparticles, (b) cardiac perfusion by cutting-edge oxygenation-sensitive cardiovascular magnetic resonance imaging (mri), (c) lung regional ventilation measured by newly developed hydrogen proton (1h) mri, (d) muscle oxygenation during exercise. 3. compare the response of the above measures to exercise intervention between young adults born very preterm and term controls.

Eligibility criteria:
inclusion criteria: both groups : * aged between 18-29 years old * less than 120 minutes of exercise per week * willingness to be part of the 14 weeks exercise intervention preterm group: - born under 29 weeks of gestation term group : * born between 37-41 weeks * appropriate weight fo gestational weight exclusion criteria: * pregnancy * conditions excludins individual from exercise

Keywords: extremely preterm young adults term exercise capacity pulmonary function muscle oxygenation
safety and pharmacologic study of vtx-2337 in patients with advanced cancer

Conditions: Advanced Solid Tumors; Lymphoma

Summary: this is a multi-center, phase i study of a new investigational drug, vtx-2337, that may stimulate the immune system to help fight cancer. the purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. the pharmacology of vtx-2337 will also be evaluated.


Eligibility criteria:
other specific eligibility criteria may apply. examination by the investigator is necessary to fully determine eligibility. inclusion criteria: * ability and willingness to provide written informed consent * histologically or cytologically confirmed solid tumors or lymphoma * locally advanced or metastatic disease * life expectancy of at least 16 weeks * ecog performance status of 0 or 1 * acceptable physical exam and laboratory tests at study entry * willingness to use medically acceptable contraception * a negative serum pregnancy test for women with reproductive potential exclusion criteria: * anticancer therapy within 2 weeks * treatment with an investigational agent within 4 weeks * systemic corticosteroids within 2 weeks or a requirement for systemic immunosuppressive therapy * known brain metastases unless stable for at least 28 days * active autoimmune disease * insulin-dependent diabetes mellitus * clinically significant cardiac disease within 6 months * significant infection or fever within 1 week * pregnant or breast-feeding females * other conditions or circumstances that could interfere with the study